GB2438682A — New use for cannabinoids
Assigned to GW Pharma Ltd · Expires 2007-12-05 · 18y expired
What this patent protects
The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and / or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol…
USPTO Abstract
The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and / or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative thereof.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.